

fluxed for 14 hr. After cooling, the mixt was washed with H₂O and extd with 10% HCl. The ext was made alk with K₂CO₃ and the oil which had sepd was extd with Et₂O. The ext was dried (K₂CO₃) and concd to dryness to give crude X as an oil. This was crystd as the oxalate. Recrystn from EtOH gave pure sample (2.8 g) as colorless prisms, mp 97–98° dec. *Anal.* (C₁₄H₂₀N₂O₂·C₂H₂O₄·0.5H₂O) C, H, N: calcd, 8.06; found, 7.41.

2-(*N*-Ethylamino)-*N'*-methylbenzanilide. A mixt of *N*-ethylisatoic anhydride² (5.75 g) and PhNHMe (3.60 g) was heated at 100° for 4 hr. at 130° for 2 hr, and at 160° for 1 hr. The mixt which crystd on cooling was recrystd from *i*-PrOH to afford pure product (5.2 g, 64%) as colorless prisms, mp 97–99°. *Anal.* (C₁₆H₁₈N₂O) C, H, N.

2-(*N*-Ethylchloroacetamido)-*N'*-methylbenzanilide. To a stirred mixt of 2-(*N*-ethylamino)-*N'*-methylbenzanilide (4.0 g, 0.016 mole) and anhyd K₂CO₃ (4.0 g, 0.028 mole) in PhH (130 ml) was added dropwise ClCH₂COCl (2.8 g, 0.024 mole) at room temp during 10 min. The mixt was stirred at room temp for 1 hr and then washed with H₂O. The dried PhH layer was concd to dryness under reduced pressure and the crystalline residue was triturated with *i*-PrOH to afford almost pure product (4.4 g, 83%), mp 137–139°. Recrystn from *i*-PrOH gave a pure sample as colorless leaflets, mp 138–140°, nmr (CDCl₃) δ 1.15 (t, *J* = 8 Hz, 3 H), 3.23 (d, q, *J* = 16 Hz, 8 Hz, 1 H), 3.32 (broad s, 2 H), 3.44 (s, 3 H), 4.29 (d, q, *J* = 16 Hz, 8 Hz, 1 H), 6.9–7.5 (m, 9 H). *Anal.* (C₁₈H₁₉ClN₂O₂) C, H, N.

2-(*N*-Ethylmorpholinoacetamido)-*N'*-methylbenzanilide (XII). A soln of 2-(*N*-ethylchloroacetamido)-*N'*-methylbenzanilide (2.0 g, 0.006 mole) and morpholine (2.6 g, 0.03 mole) in PhH (30 ml) was warmed at 50° for 3 hr and then washed with H₂O. The dried PhH layer was concd to dryness under reduced pressure to give almost pure product as a colorless oil, nmr (CDCl₃) δ 1.13 (t, *J* = 7 Hz, 3 H), 2.46 (m, 4 H), 2.63 (s, 2 H), 3.19 (d, q, *J* = 14 Hz, 7 Hz, 1 H), 3.40 (s, 3 H), 3.65 (m, 4 H), 4.17 (d, q, *J* = 14 Hz, 7 Hz, 1 H), 6.9–7.5 (m, 9 H).

2-(Morpholinoacetamido)benzanilide (XI). A soln of 2-(chloroacetamido)benzanilide (5.57 g) and morpholine (4.3 g) in dioxane (180 ml) was stirred at 60–65° for 20 hr. The reaction mixt was concd under reduced pressure and the residue was poured into H₂O. The crystals were collected by filtration to give crude XI (6.9 g). Recrystn from dioxane afforded 6.2 g (94%) of XI as colorless prisms, mp 189–191°; the analytical sample melted at 190–192°. *Anal.* (C₁₉H₂₁N₃O₃) C, H, N. The hydrochloride was obtained as colorless needles (aqueous MeOH), mp 230–231° dec. *Anal.* (C₁₉H₂₁N₃O₃·HCl) C, H, N.

Acknowledgments. The authors wish to thank Mr. T. Takayanagi, Manager of Development Division, and Dr. K. Fujii for their encouragement.

References

- (1) K. Okumura, T. Oine, Y. Yamada, G. Hayashi, M. Nakama, and T. Nose, *J. Med. Chem.*, **11**, 788 (1968) (paper 2).
- (2) K. Okumura, T. Oine, Y. Yamada, G. Hayashi, and M. Nakama, *ibid.*, **11**, 348 (1968).
- (3) G. Bonola, P. Da Re, M. J. Magistretti, E. Massarani, and I. Setnikar, *ibid.*, **11**, 1136 (1968).
- (4) M. Pozzi, *Farmaco Ed. Prat.*, **24**, 655 (1969).
- (5) I. Setnikar and V. De Fina, *Toxicol. Appl. Pharmacol.*, **16**, 571 (1970).
- (6) I. Setnikar and M. J. Magistretti, *Arzneim.-Forsch.*, **20**, 1559 (1970).
- (7) Y. V. Kozhevnikov and P. A. Petyunin, *Khim. Geterotsikl. Soedin.*, 747 (1969).
- (8) R. N. Castle, K. Adachi, and W. D. Guither, *J. Heterocycl. Chem.*, **2**, 459 (1965).
- (9) G. S. Mewada, S. R. Patel, and N. M. Shah, *J. Indian Chem.*, **32**, 483 (1955).

Basic Ethers of 2-Anilinobenzothiazoles and 2-Anilinobenzoxazoles as Potential Antidepressants

C. J. Sharpe,* P. J. Palmer, D. E. Evans, G. R. Brown, Gillian King, R. S. Shadbolt, R. B. Trigg, R. J. Ward,

Chemistry Department

A. Ashford, and Janet W. Ross

Pharmacology Department, Twyford Laboratories Ltd., London N.W.10., England. Received September 1, 1971

Some 2-[4-(β-*tert*-aminoethoxy)anilino]benzothiazoles and the corresponding benzoxazoles reversed reserpine-induced hypothermia in mice at low doses. The effects of structural variation of these molecules have been systematically examined. General pharmacology of selected compounds classifies them as antidepressants with a mild stimulant component. Anilinobenzazoles were advantageously prepared from substituted anilines and 2-chlorobenzazoles in DMF or *sym*-tetrachloroethane.

Routine pharmacological screening in these laboratories of compounds prepared for another purpose¹ revealed significant activity of 2-[4-(β-diethylaminoethoxy)phenyl]benzothiazole (1) in reversing reserpine-induced hypothermia in mice. This paper describes structural modifications leading to compounds having greatly increased antireserpine activity and a general pharmacological profile which suggests that they may be of value in depressive illness.











It soon became clear that in the 2-phenylbenzothiazole and 2-phenylbenzoxazole series, antireserpine activity was limited to a few basic ethers such as 1 in which a variety of substituents in the benzene ring did not greatly alter the activity. The 2'- and 3'-diethylaminoethoxy isomers of 1 were inactive, as were several 2-phenylbenzothiazoles having groups other than a basic ether in the 4' position. The introduction of bridging groups Y (Table I) between the benzazole and Ph rings led to the considerable increase in potency

of the anilino basic ether 3, other N-containing bridging groups being less effective and those without N giving weak or inactive compds. Compd 3 has been reported to have hypcholesterolemic activity.² The importance of the anilino H atom is shown by the poor activity of the *N*-Me and *N*-Ac derivs 17 and 18.

Tests on intermediates (Table II) suggested that the basic structural unit required for antireserpine activity was *p*-ZNHC₆H₄O(CH₂)_nNR₂ and that potency was greatly increased when Z was an electron-attracting aromatic group. When Z was *p*-nitrophenyl the diphenylamine basic ether² 52, although a potent antireserpine compd, caused a severe stereotyped response in the cat (see below). Other nuclei employed as Z produced compds which, as potential antidepressants, had pharmacological profiles inferior to those of the anilinobenzazoles (e. g., 3, 14). Since the benzimidazole 16 was almost inactive, further variations were made in the basic ethers of 2-anilinobenzothiazoles and benzoxazoles (Tables I and III).

*Address correspondence to this author at: 76 Elms Road, Harrow Weald, Middlesex, HA3 6BS, England.

Table 1

No.	X	Y	R	Prep ^a	% yield	Mp or bp (mm), °C	Recryst ^b solvent	Formula ^c	Cat behavior ^e		
									Reserpine ^d	Dose, mg/kg	Intensity
1	S		OCH ₂ CH ₂ NEt ₂	f					39		
2	S	O	OCH ₂ CH ₂ NEt ₂	g					i		
3	S	NH	OCH ₂ CH ₂ NEt ₂	A ^h	46	92-93	Petr (60-80°)		12.4	50	+++
4	S	SCH ₂	OCH ₂ CH ₂ NEt ₂	g					w		
5	S	CH ₂	OCH ₂ CH ₂ NEt ₂	D	60	95 ⁱ	EtOH-Et ₂ O	C ₂₂ H ₂₆ N ₂ O ₅ S ^{l,j}	i		
6	S	(CH ₂) ₂	OCH ₂ CH ₂ NEt ₂	g					51	25	i
7	S	(CH ₂) ₃	OCH ₂ CH ₂ NEt ₂	D ₁	64	101-102 dec ^k	Me ₂ CO	C ₂₈ H ₃₆ N ₂ O ₈ S ^k	i		
8	S	S	OCH ₂ CH ₂ NEt ₂	g					w		
9	S	NHCH ₂	OCH ₂ CH ₂ NEt ₂	g					>50		
10	S	CH ₂ NH	OCH ₂ CH ₂ NEt ₂	E ₁	20	111 dec ^l	Me ₂ CO	C ₂₀ H ₂₆ ClN ₃ OS ^{l,o}	44		
11	S	NHCO	OCH ₂ CH ₂ NEt ₂	E ₂	28	254-256 ^l	DMF-Et ₂ O	C ₂₀ H ₂₄ ClN ₃ O ₂ S ^{l,m}	25		
12	S	CONH	OCH ₂ CH ₂ NEt ₂	E ₃	87	95.5-96.5	Hex	C ₂₀ H ₂₃ N ₃ O ₂ S	22.5		
13	S	NHCSNH	OCH ₂ CH ₂ NEt ₂	E ₄	14	187-188	PhCl	C ₂₀ H ₂₄ N ₂ O ₅ S ₂	i		
14	O	NH	OCH ₂ CH ₂ NEt ₂	A	49	73-74	Petr (60-80°)	C ₁₉ H ₂₃ N ₃ O ₂	9.8	30	+++
15	O	(CH ₂) ₂	OCH ₂ CH ₂ NEt ₂	D ₁	85	122-123 ^k	MeCOEt	C ₂₇ H ₃₄ N ₂ O ₉ ^k	87		
16	NH	NH	OCH ₂ CH ₂ NEt ₂	A	20	123-124	PhH-hex	C ₁₉ H ₂₃ N ₄	w		
17	S	NMe	OCH ₂ CH ₂ NEt ₂	A	80	Oil		C ₂₀ H ₂₅ N ₃ OS ⁿ	45		
18	S	NAc	OCH ₂ CH ₂ NEt ₂	E ₅	80	88-89	Petr (60-80°)	C ₂₁ H ₂₅ N ₃ O ₂ S	w		
19	S	NH	OCH ₂ CH ₂ NMe ₂	B ₂	50	p		C ₁₇ H ₁₉ N ₃ OS	33		
20	S	NH	OCH ₂ CH ₂ NPr ₂	A	36	86.5-87.5	Petr (60-80°)	C ₂₁ H ₂₇ N ₃ OS	20		
21	S	NH	OCH ₂ CH ₂ NBu ₂	A	41	79-80	Petr (40-60°)	C ₂₃ H ₃₁ N ₃ OS	w		
22	S	NH	OCH ₂ CH ₂ N(CH ₂ Ph) ₂	A	37	103-104	EtOH	C ₂₉ H ₂₇ N ₃ OS	w		
23	S	NH	OCH ₂ CH ₂ N(CH ₂ CH ₂ OH) ₂	B	36	101-102.5	EtOAc	C ₁₉ H ₂₃ N ₃ O ₃ S	w		
24	S	NH	OCH ₂ CH ₂ N 	A	50	131.5-132	EtOH	C ₁₉ H ₂₁ N ₃ O ₂ S	25		
25	S	NH	OCH ₂ CH ₂ N 	B	49	168-169	EtOAc	C ₂₀ H ₂₄ N ₄ OS	w		
26	S	NH	OCH ₂ CH ₂ N 	B	63 ^q	138-139	EtOAc	C ₂₀ H ₂₃ N ₃ OS	3.5	35	++
27	S	NH	OCH ₂ CH ₂ N 	B ₁	52	135.5-137	EtOH-H ₂ O	C ₁₉ H ₂₁ N ₃ OS	3.7	50	i
28	S	NH	OCH ₂ CH ₂ N 	B ₁	33	115-116	EtOH-H ₂ O	C ₂₁ H ₂₅ N ₃ OS	8.8		
29	S	NH	OCH ₂ CH ₂ N 	E ₆	70	183-184	EtOH-H ₂ O	C ₂₁ H ₂₁ N ₃ OS	>20		
30	S	NH	OCH ₂ CH ₂ NH ₂	E ₇	63	146.5-147.5	PhH	C ₁₅ H ₁₅ N ₃ OS	i		
31	S	NH	OCH ₂ CH ₂ NH ₂ Et	B ₃	65	126-127	PhH-ligroin	C ₁₇ H ₁₉ N ₃ OS ^r	42		
32	S	NH	OCH ₂ CH ₂ N(Et)CH ₂ CH ₂ OH	B	40	68-70	s	C ₁₉ H ₂₃ N ₃ O ₂ S	32		
33	S	NH	OCH ₂ CH ₂ N(Me)Et	B ₄	72	116.5-117.5	PhH-Hex	C ₁₈ H ₂₁ N ₃ OS	16		
34	S	NH	OCH ₂ CH ₂ N(Et)Pr	B ₄	40	79-79.5	Petr (40-60°)	C ₂₀ H ₂₅ N ₃ OS	5.3	50	++
35	O	NH	OCH ₂ CH ₂ NMe ₂	B ₂	70	106.5-107	Petr (60-80°)	C ₁₇ H ₁₉ N ₂ O ₂	28		
36	O	NH	OCH ₂ CH ₂ N 	B	48	160-161	EtOAc	C ₁₉ H ₂₁ N ₃ O ₃	16.5		
37	O	NH	OCH ₂ CH ₂ N 	B	57	131-132	EtOAc	C ₂₀ H ₂₃ N ₃ O ₂	4.1	30	++
38	O	NH	OCH ₂ CH ₂ N 	B ₁	72	129-130 ^t	EtOH-H ₂ O	C ₁₉ H ₂₁ N ₃ O ₂	4.3	50	i
39	S	NH	OCH(Me)CH ₂ NEt ₂	A	55	108-110	Petr (60-80°)	C ₂₀ H ₂₅ N ₃ OS	>50		
40	S	NH	O(CH ₂) ₃ NEt ₂	D	20	92-93	Hex	C ₂₀ H ₂₅ N ₃ OS	14.8		
41	S	NH	O(CH ₂) ₄ NEt ₂	A	18	86-86.5	Petr (60-80°)	C ₂₁ H ₂₇ N ₃ OS	62		
42	S	NH	CH ₂ CH ₂ NEt ₂	A ₁	16	99-100	Petr (60-80°)	C ₁₉ H ₂₃ N ₃ S	>20		
43	S	NH	(CH ₂) ₃ N 	B	70	103-104	Petr (60-80°)	C ₂₁ H ₂₅ N ₃ S	14	25	i
44	S	NH	(CH ₂) ₄ NEt ₂	A ₁	40	94-95	Petr (60-80°)	C ₂₁ H ₂₇ N ₃ S	20		
45	S	NH	NHCH ₂ CH ₂ NEt ₂	A	36	119-119.5	MeOH	C ₁₉ H ₂₃ N ₄ S	24.5		
46	S	NH	SCH ₂ CH ₂ NEt ₂	A ₁	60	81-82	PhH-petr (60-80°)	C ₁₉ H ₂₃ N ₃ S ₂	w		

^aEntries refer to general methods of prepn described in the Experimental Section. ^bPetr = petroleum ether (boiling range given), Hex = *n*-hexane. ^cCompds whose formulas are given, gave analyses for C, H, and N within 0.4% of the theoretical values unless otherwise annotated. ^dReversal of reserpine-induced hypothermia in mice as described in ref 4. Figures denote ED₅₀ mg/kg po; w = ED₅₀ > 100 mg/kg; i = no activity at 100 mg/kg. Doses are calcd as the free base. ^eCat behavior test as described in ref 4; (+) nervousness, (++) stereotyped reactions, (+++) severe stereotyped reactions. ^fRef 19. ^gRef 38. ^hPreviously prepd by other methods, ref 2 and 38. ⁱOxalate. ^jAnal. H, N; C: calcd 61.4; found 60.8. ^kCitrate. ^lHydrochloride. ^mAnal. C, H; N: calcd 10.3; found 9.7. ⁿAnal. H, N; C: calcd 67.6; found 67.0. ^oAnal. C, H, N, Cl, S. ^pObtd in allotropic forms, mp 138-139° (EtOAc) and mp 147-148° (EtOH), Anal. (C₁₇H₁₉N₃OS) in each case. Citrate mp 168-169° dec (MeOH). Anal. (C₂₃H₂₇N₃O₈S). ^qAlso by method A₁, yield 70%. ^rAnal. H, N; C: calcd 65.2; found 65.9. *N,N'*-Diacetyl deriv (Ac₂O, AcOH, 100°), mp 150.5-151.5° (EtOAc). Anal. (C₂₁H₂₃N₃O₃S). ^sPurified *via* the dipicrate, mp 182-183° (MeOCH₂CH₂OH). The base was recovered by treatment with 2*N* NaOH and chromatogd on alumina with PhH-CHCl₃, 4:1. ^tRecrystn from PhH or EtOAc gave products, mp *ca.* 116°, containing solvent which was retained at 80° (0.2 mm). Unsolvated product was recovered by recrystn from EtOH-H₂O.

Table II. *p*-Z_nNHC₆H₄OCH₂CH₂R³ and Reference Compounds

No.	Z	R ³	Prep ^a	% yield	Salt	Mp or bp (mm), °C	Recryst ^b solvent	Formula ^c	Reserpine ^d	Cat behavior ^e	
										Dose, mg/kg	Intensity
47	H	NEt ₂	f	73	Base	65-67			20.5		
48	H	Piperidimyl	g	64	Base	126-127 (0.05)		C ₁₄ H ₂₄ N ₂ O	8		
49	Et	NEt ₂	E ₈						32		
50	PhNHC(S)-	NEt ₂	h	44	HCl	181-182	EtOH	C ₁₈ H ₂₂ ClN ₂ O	w		
51	Ph	NEt ₂	D ₁						23.5		+++
52	4-NO ₂ C ₆ H ₄	NEt ₂	i	35	Citrate	106-107	MeOH-Et ₂ O	C ₂₂ H ₃₄ N ₂ O ₉	43		
53	4-MeOC ₆ H ₄	NEt ₂	E ₉	36	Base	204-206 (0.01)		C ₂₂ H ₃₆ N ₂ O	20		
54	2-Naphthyl	NEt ₂	D ₁	50	HCl	182-183	MeOH-Et ₂ O	C ₁₃ H ₂₂ ClN ₃ OS ^j	35		
55	2-Thiazolyl	NEt ₂	E ₁₀	10	Base ^k	176-178 (0.05)			w		
56	2-Pyridyl	NEt ₂	A ₂		Dipicrate	187-188	MeOCH ₂ CH ₂ OH	C ₂₃ H ₂₉ N ₉ O ₁₅ ^{j,l}	>50		
57	2-Quinolyl	NEt ₂	A ₂	20	Base	223 (0.01)	MeOCH ₂ CH ₂ OH	C ₃₅ H ₅₁ N ₉ O ₁₅	i		
58	2-Btz-NH(CH ₂) ₂ OCH ₂ CH ₂ NEt ₂ ^m		E ₁₁	44	Dipicrate	187-188		C ₁₆ H ₂₅ N ₃ OS	6.2		+++
Imipramine ⁿ						Oil ^k			2.0		
Nortriptyline ⁿ									0.6		
dl-Amphetamine ^o											

^aAs in Table I. ^fRef 22. ^gSee Experimental Section under intermediates. ^hRef 24. ⁱRef 2. ^jAnal. C, H, Cl. ^kSee Experimental Section. ^lAnal. H, N; C: calcd 46.9; found 47.5. ^m2-Btz = 2-benzothiazolyl. ⁿAs HCl. ^oAs sulphate.

The greatest changes in antireserpine activity resulted from varying the terminal basic group (*cf.* Tables I and III). By comparison with the diethylamino compd **3**, activity was reduced with other dialkylamino groups except NEtPr, **34**, but potent compds were obtained when NR₂ was a piperidine or pyrrolidine ring (*e. g.*, **26**, **27**). The optimum chain length resulted when *n* = 2 in the general structure above and replacement of the ether oxygen by CH₂, NH, or S (**43**, **45**, **46**) gave less active compds.

Benzene ring substitution (Table III) in most cases reduced the activity, but some increase resulted with a Me or MeO group in the 5 position (**63**, **64**) when the terminal group was NEt₂. Also the reduction in activity resulting from 5-Cl or 5-CF₃ substitution (**62**, **66**, **71**) suggests that the electronic nature of substituents in the 5 position influences the activity. In the diphenylamines **52** and **53**, however, the effects are different since the electron-attracting NO₂ group gives the more active compd.

The pharmacological properties of selected anilinobenzazoles resembled those of imipramine and other tricyclic antidepressants in several respects, but they had a much weaker anticholinergic effect and showed little depressant activity. Their actions included a mild stimulant component, suggesting antidepressant properties intermediate between those of imipramine and amphetamine. The anilinobenzazoles were very similar pharmacologically to a previously reported series of phenacylmercaptoimidazolines,³ although there is no obvious structural relationship between the two series. In both series some compds at a relatively high dose caused amphetamine-like behavioral changes in cats, ranging from nervousness to stereotyped reactions, as previously described,⁴ but some members of the present series (*e. g.*, **27**, **38**, and **79**) had no effect or caused only mild stereotypy and the ratios of the CNS-stimulant dose to the antireserpine ED₅₀ were as good as or superior to those of the imidazolines.

The benzoxazoles **14** and **38** were teratogenic in rats, but the closely related benzothiazoles **27** and **79** have not shown this property although extended tests remain to be carried out.

The pharmacological results are given in more detail in the Experimental Section.

Chemistry. The preparation of anilinobenzazoles by reaction between a 2-halogenobenzazole and a substituted aniline^{5,6} proved more generally useful when DMF or (Cl₂CH)₂ was used as solvent. Use of DMF gave rise to variable amounts of the 2-dimethylaminobenzazoles, making purification of some products more difficult. 2-Chlorobenzothiazole gave a 65% yield of the 2-Me₂N deriv after 5-hr boiling in DMF which was initially freed of Me₂NH. The surprisingly good results with (Cl₂CH)₂ may be due to a catalytic effect of the HCl produced by decompn of the solvent, which could further activate the benzazole halogen by salt formation.⁷ This view was supported by the reactivity of the crystalline BF₃ salt of 2-chlorobenzoxazole, which gave a 64% yield of 2-[4-(β-chloroethoxy)anilino]benzoxazole, at the bp of CH₂Cl₂, although this type of reaction was too variable to be of general use. Comparative results using DMF or Cl₂CHCHCl₂ were only obtained in a few cases and the solvent used is not necessarily that of choice; (Cl₂CH)₂ seemed superior for anilines lacking a second basic group.

Because of difficulties experienced in the preparation of 2-chlorobenzoxazoles from 2-mercaptobenzoxazoles, direct treatment of the latter with anilines⁸ was preferred in spite of the necessity for chromatography of the products.

Table III

No.	R ¹	X	R ²	R ³	Prep ^a	% yield	Mp, °C	Recryst ^b solvent	Formula ^c	Reserpine ^d	Cat behavior ^e	
											Dose, mg/kg	Intensity
59	4-Cl	S	H	NEt ₂	A	57	104.5-105.5	PhH-petr (60-80°)	C ₁₉ H ₂₂ ClN ₃ OS ^f	62		
60	4-Me	S	H	NEt ₂	A ₁	25	92-93	Petr (60-80°)	C ₂₀ H ₂₅ N ₃ OS	21	25	i
61	4-MeO	S	H	NEt ₂	A	15	118-119	Petr (80-100°)	C ₂₀ H ₂₅ N ₃ O ₂ S	23	25	+
62	5-Cl	S	H	NEt ₂	A	60	179.5-180.5	PhH-petr (60-80°)	C ₁₉ H ₂₂ ClN ₃ OS	27		
63	5-Me	S	H	NEt ₂	A	35	141-142	Petr (80-100°)	C ₂₀ H ₂₅ N ₃ OS	10.1	25	i
64	5-MeO	S	H	NEt ₂	C	10	163-164	EtOH-H ₂ O	C ₂₀ H ₂₅ N ₃ O ₂ S	4.2	75	+
65	5-NO ₂	S	H	NEt ₂	A ₁	30	149-150	MeOH	C ₁₉ H ₂₂ N ₃ O ₂ S	w		
66	5-CF ₃	S	H	NEt ₂	A	60	186-186.5	Petr (100-120°)	C ₂₀ H ₂₂ F ₃ N ₃ OS	>50		
67	5-AcNH	S	H	NEt ₂	A ₁	20	202-203	PhH	C ₂₁ H ₂₆ N ₄ O ₂ S	i		
68	6-Cl	S	H	NEt ₂	A	54	106-107	PhH-petr (60-80°)	C ₁₉ H ₂₂ ClN ₃ OS	12.6	25	+
69	6-Me	S	H	NEt ₂	A	35	88-89	Petr (60-80°)	C ₂₀ H ₂₅ N ₃ OS	10.7	25	+
70	6-NO ₂	S	H	NEt ₂	A	75	170-170.5	EtOH	C ₁₉ H ₂₂ N ₄ O ₃ S ^g	23.2		
71	5-Cl	O	H	NEt ₂	A ₁	55	117-118	PhH-Hex	C ₁₉ H ₂₂ ClN ₃ O ₂	14.5	25	-
72	5-Me	O	H	NEt ₂	C	42	106-107	Petr (100-120°)	C ₂₀ H ₂₅ N ₃ O ₂	5.4	50	+
73	5-PhCH ₂ O	O	H	NEt ₂	C	32	120.5-121	Petr (100-120°)	C ₂₆ H ₂₉ N ₃ O ₃	w	50	+
74	6-Cl	O	H	NEt ₂	C	40	100-101	Hex	C ₁₉ H ₂₂ ClN ₃ O ₂	13	25	i
75	6-Me	O	H	NEt ₂	C	29	97-98	PhH	C ₂₀ H ₂₅ N ₃ O ₂	16	20	+
76	6-NO ₂	O	H	NEt ₂	C ₁	40	160-160.5	PhH	C ₁₉ H ₂₂ N ₄ O ₄	28		
77	5-Me	S	H	PyrrolidinyI	A	14	153-154	EtOH-H ₂ O	C ₂₀ H ₂₃ N ₃ OS	3.5	50	++
78	5-Me	O	H	PyrrolidinyI	C	43	144-145	PhH	C ₂₀ H ₂₃ N ₃ O ₂	2.3	50	++
79	5-MeO	S	H	PyrrolidinyI	B ₁	80	167-167.5	PhH	C ₂₀ H ₂₃ N ₃ O ₂ S	3.1	50	+
80	6-Cl	S	H	PiperidinyI	A	25	148-149	EtOH	C ₁₉ H ₂₂ ClN ₃ OS	13		
81	6-MeO	S	H	PiperidinyI	B	55	118-119	EtOH-H ₂ O	C ₂₁ H ₂₅ N ₃ O ₂ S	8.6		
82	6-Cl-5-MeO	S	H	PiperidinyI	B ₁	68	177-178	PhH	C ₂₁ H ₂₄ N ₃ O ₂ S	>20		
83	5,6-Me ₂	O	H	PiperidinyI	A ₁	50	142-144	EtOAc	C ₂₂ H ₂₇ N ₃ O ₂	7.7		
84	H	S	2'-Me	NEt ₂	D	20	113-114	Petr (60-80°)	C ₂₀ H ₂₅ N ₃ OS ^h	>50	20	-
85	H	S	3'-Cl	NEt ₂	A ₁	55	114-115	PhH-petr (60-80°)	C ₁₉ H ₂₂ ClN ₃ OS ⁱ	4 i		
86	H	S	3'-5'-Me ₂	NEt ₂	A ₁	60	Liq ^j		C ₂₁ H ₂₇ N ₃ OS	21		
87	H	S	2'-Me-5'-i-Pr	NEt ₂	A ₁	40	134.5-135.5	Petr (60-80°)	C ₂₃ H ₃₁ N ₃ OS	i		

^{a-e}As in Table I. ^fAnal. H, N, C: calcd 60.7; found 60.2. ^gAnal. C, H, S; N: calcd 14.5; found 14.0. ^hAnal. C, N, H: calcd 7.1; found 7.55. ⁱAnal. C, H, N, Cl. ^jPurified by chromatog on alumina (5% EtOH in Et₂O).

The reaction between 2-mercapto-5-methoxybenzothiazole and SO₂Cl₂⁹ even at 0° gave a dichloro compd assumed to be the 2,6-dichloro-5-methoxy deriv. The reactivity of the 2-chlorobenzazoles toward anilines was qualitatively similar to that with alkoxide ions¹⁰ in that 5- or 6-OMe substituents were deactivating and 5- or 6-NO₂ were activating.

Other products and intermediates were obtained by adaptation of standard procedures as given in the Experimental Section.

Experimental Section

Pharmacology. Compds were administered orally either as soluble salts or in 0.5% tragacanth suspension in the mouse and rat tests, control animals receiving the vehicle alone. In the cat behavior study⁴ compds were given orally in gelatine capsules. Doses are expressed as the free base. All compds were screened by the reserpine hypothermia test in mice as previously described⁴ and cat behavior was studied on selected compounds. The results are given in the tables.

More detailed pharmacological study was carried out on compds 3, 14, 26, 37, 38, and 79 and more particularly on 38 and 79. Both 38 and 79 showed properties in common with those of tricyclic antidepressants in that they antagonized an established reserpine hypothermia, prevented tetrabenazine sedation in the rat, inducing instead a compulsive motor activity¹¹ at 20-25 mg/kg and enhanced the agonist effects of norepinephrine on the isolated rat vas deferens.¹² Neither compd potentiated tryptamine convulsions in mice¹³ and therefore did not appear to inhibit MAO, but both, like imipramine, potentiated the stimulant effect of dopa in mice in which MAO was partially inhibited by iproniazid.¹⁴ The anticholinergic and antihistaminic properties of 38 and 79 were weaker than those of imipramine as assessed by ACh-induced chromodacryorrhoea in rats and on the isolated guinea pig ileum. Compd 38 showed a

marked antagonism of an established tremorine hypothermia but less effect against tremor and 79 behaved similarly against oxotremorine, both compds resembling imipramine in this respect.¹⁵ Neither 38 nor 79 affected normal rectal temp nor prevented nor reversed chlorpromazine hypothermia in mice. No analeptic activity was evident against pentobarbital lethality in mice. Both substances antagonized maximal pentylenetetrazole¹⁶ and electroshock convulsions¹⁷ in mice (ED₅₀ = 54-70 mg/kg). Against phenylquinone writhing in mice the ED₅₀ was 5-8 mg/kg but no other analgetic or antiinflammatory properties were detected. Mild anorexia occurred in rats⁴ at 25-50 mg/kg.

The acute LD₅₀ in mice was 670-680 mg/kg, the minimal convulsant dose being 400-500 mg/kg. The compds differed from imipramine in causing a state of alertness and increased sensitivity. In rodents this appeared at doses of 50-100 mg/kg following a brief depressed period and in cats and dogs nervousness or slight stereotyped reactions occurred at 50-75 mg/kg. In single squirrel monkeys, 10 or 25 mg/kg of 38 caused a slight increase in motor activity; at 40 mg/kg the monkey showed a tendency to look around with jerky head movements. In the baboon, 20 mg/kg of 79 caused a slight increase in motor activity.

Repeat dosing of 38 in rats for 14 days at 10, 30, or 100 mg/kg per day caused a significantly reduced body wt gain at 30 and 100 mg and a significantly increased adrenal wt in the female rats at the 100-mg dose. In dogs, 5 mg/kg per day for 6 months had no effect whereas 10 mg/kg per day caused a slight uneasiness and reduction in appetite, and 15 and 45 mg/kg per day caused some fear, quietness, confusion, stereotyped reaction, anorexia, and reduction in wt gain. At 45 mg/kg per day the liver, thymus, and adrenals were significantly increased, and the pancreas significantly decreased, in wt. The hematological profile was not altered at any dose level in either species.

In teratogenic tests in rats 38 given at 25 or 50 mg/kg per day on days 0-19 of pregnancy or 60 mg/kg per day on days 5-15, caused malformations in 4, 33, and 27% of fetuses, resp; the malformations affected mainly the ribs, which were "wavy", and the

sternebrae, which were often bifurcated. There was a general lack of ossification of the skull, vertebrae, sternebrae, ribs, and forelimbs. In New Zealand White rabbits, 38 at 20, 40, and 60 mg/kg per day on days 0-28 caused abnormalities in 3, 5, and 62% of fetuses, respectively, mainly in the form of absent or malformed phalanges of the paws. In the rat and rabbit tests however, the 50 and 60 mg/kg doses caused behavioral effects, anorexia, and depressed body wt increase in the mothers.

Compd 14 was shown to be markedly teratogenic in rats, causing 42% abnormalities at 60 mg/kg per day on days 5-15 whereas the benzothiazole 27 showed no definite evidence of teratogenicity at 15, 30, and 60 mg/kg per day, suggesting that this effect may be associated with the benzoxazole nucleus. Also, the benzothiazole 79 showed no gross teratogenic effects when given at 25 and 50 mg/kg per day; results of the examination of the skeletons are not available.

Chemistry. Mps were detd in capillary tubes in a Büchi apparatus and are corrected. Chromatog materials were alumina type H (Spence) deactivated by addn of 5% w/w of 10% HOAc and silica for chromatography (Merck), 0.2-0.5 mm, solvents quoted are those which elute the required product from the column. Petr = petroleum ether (boiling range given). Solvent exts of aqueous mixts were washed (H₂O), dried (MgSO₄), and evapd at 40-50° (ca. 20 mm) unless stated otherwise. Where analyses are indicated only by symbols of the elements analytical results for those elements were within ±0.4% of the theoretical values; compds for which only formulas are given were analyzed for C, H, and N. Ir and uv spectra were consistent with the structures assigned.

General Methods of Preparation. A. A soln of a 2-chlorobenzazole (or for 59, 2-bromo-4-chlorobenzothiazole¹⁸) (0.05 mole) and a substituted aniline (0.05 mole) in DMF (40 ml) was boiled under reflux for 6 hr under N₂. The soln was dild with 2 N HCl and washed with Et₂O. The acid soln was basified (NaOH soln) and the product was isolated by Et₂O extn and purified if necessary by chromatography on alumina with PhH or Et₂O.

A₁. The reactants as in A and Cl₂CHCHCl₂ (80 ml) were boiled under reflux for 4 hr, concd at reduced pressure, and worked up as in A.

A₂. 4-(β-Diethylaminoethoxy)aniline (0.1 mole) and 2-bromopyridine or 2-bromoquinoline (0.1 mole) were heated at 200° for 6 hr, cooled, and worked up as in A. The products were dist using a 15-cm Vigreux column. The anilinoquinoline 56 was purified *via* its dipicrate (Table II) from which the base was recovered by decompn with 40% NaOH soln.

B. A soln of a 2-[4-(ω-chloroalkoxy)anilino]benzazole or a 2-[4-(ω-chloroalkyl)anilino]benzazole (0.1 mole) and an amine (0.3 mole) in PhMe (300 ml) were boiled under reflux for 16 hr. The soln was extd with 2 N HCl and the acid ext was basified with 10 N NaOH. The product was isolated by Et₂O extn and, if necessary, was chromatogd on alumina with CHCl₃.

B₁. The reactants of method B in MeOCH₂CH₂OH (150 ml) were boiled under reflux for 1 hr. The soln was evapd at reduced pressure and the residue was worked up as in method B.

B₂. A 2-[4-(ω-chloroalkoxy)anilino]benzazole (0.01 mole), an amine (0.03 mole), EtCOMe (30 ml), and NaI (0.2 g) were heated in a sealed tube at 90° for 16 hr. The mixt was evapd and worked up as in method B.

B₃. A 2-[4-(ω-chloroalkoxy)anilino]benzazole (0.01 mole) and a large excess of an amine were heated in a sealed tube at 120° for 4 hr, evapd, and worked up as in B.

B₄. As in B₃ but with the addn of NaI (50 mg) and DMF (15 ml).

C. A 2-mercaptobenzoxazole (0.01 mole), a substituted aniline (0.01 mole), and *o*-dichlorobenzene (15 ml) were boiled under reflux for 16 hr. The soln was extd with 2 N HCl, the acid ext was basified with 10 N NaOH, and the product, obtd by EtOAc extn, was purified by chromatog, first on silica with Me₂CO and then on alumina with CHCl₃.

C₁. As described in method C but using Cl₂CHCHCl₂ as solvent.

D. An appropriate phenol in acetone with anhyd K₂CO₃ was alkylated with a diethylaminoalkyl chloride.¹⁹

D₁. As in D but using EtOH-NaOEt as the medium.¹⁹

Miscellaneous Methods. E₁. 2-Chloromethylbenzothiazole (0.01 mole) and 4-(β-diethylaminoethoxy)aniline (0.01 mole) in xylene (50 ml) were boiled under reflux for 18 hr and cooled, and the gummy ppt was extd with hot Me₂CO to obtain the HCl salt, which crystd from the ext.

E₂. 2-Aminobenzothiazole (1.1 g) in pyridine (50 ml) was aroylated with 4-(β-diethylaminoethoxy)benzoyl chloride²⁰ in the usual way and the soln was evapd to obtain the crude HCl salt.

E₃. 4-(β-Diethylaminoethoxy)aniline reacted with benzo-1,4-thiazine-2,3-dione in HOAc as described using aniline.²¹ The soln was evapd, dild with H₂O, and basified. The product was isolated by EtOAc extn and purified by chromatog on alumina (PhH-hexane, 3:1).

E₄. 4-(β-Diethylaminoethoxy)phenyl isothiocyanate⁴ (0.05 mole) and 2-aminobenzothiazole (0.05 mole) were heated at 100° for 5 hr. The product crystd on trituration with CH₃CN.

E₅. Compd 3 (1 g) was heated with Ac₂O (3 ml) for 3 hr at 100°, the mixt was poured into H₂O, made alk with NH₄OH, and extd with Et₂O.

E₆. 2-[4-(β-Aminoethoxy)anilino]benzothiazole (30) (0.57 g), hexane-2,5-dione (0.5 g), EtOH (20 ml), EtOAc (20 ml), and HOAc (1 drop) were boiled for 3 hr under reflux and evapd.

E₇. A soln of 2-[4-(β-azidoethoxy)anilino]benzothiazole (3.8 g) in THF (125 ml) was added to LAH (6 g) in Et₂O (200 ml) and boiled for 2 hr. The usual work-up gave a solid which was easily distinguishable from the starting azide by its ir spectrum.

E₈. 4-(β-Diethylaminoethoxy)acetanilide²² (0.03 mole) was reduced with LAH (0.06 mole) in Et₂O with 1.5-hr boiling.

E₉. A soln of 4-hydroxy-4'-methoxydiphenylamine²³ (5 g) in HOAc (25 ml) and Ac₂O (25 ml) was allowed to stand overnight and poured into H₂O to give the *N*-Ac deriv (5.9 g); mp 160-165°. This was added to a stirred suspension of NaH (1.06 g) in DMF (100 ml) followed after 5 min by a soln of β-diethylaminoethyl chloride · HCl (3.8 g) in DMF (50 ml) and the mixt was stirred at 95° for 5 hr. The solvent was evapd and the residue was mixed with 2 N NaOH and Et₂O. The product from the Et₂O layer (6.4 g, brown oil) was boiled with 5 N HCl (150 ml; 16 hr) and the basic ether was isolated in the usual way and dist (4.7 g); bp 202-204° (0.01 mm).

E₁₀. 4-(β-Diethylaminoethoxy)phenylthiourea²⁴ (1.44 g), ClCH₂CH(OEt)₂ (0.82 g), 2 N H₂SO₄ (5 ml), and EtOH (20 ml) were boiled for 3 hr under reflux, the EtOH was evapd, and the residue was shaken with 2 N NaOH and Et₂O. The product in the Et₂O layer was extd into 2 N HCl, basified, isolated by Et₂O extn, and dist (1 g); bp 205-206° (0.1 mm). The hydrochloride was obtained by evapn of a 1 N HCl soln of the base.

E₁₁. Use of 3-(β-diethylaminoethoxy)propylamine²⁵ in method A and purification by chromatog on alumina [PhH-petr (60-80°) 1:1] gave the product as a colorless oil.

Intermediates. Substituted Anilines Used in Methods A, A₁, and A₂. 4-(β-Tosyloxy)ethoxyacetanilide reacted with amines as previously reported⁴ to give the following *p*-XCH₂CH₂OC₆H₄NH₂: X = NPr₂, 79%, bp 170-172 (4 mm), di-HCl mp 201-202 dec (EtOH-H₂O) [Anal. (C₁₄H₂₆Cl₂N₂O)]; X = piperidino, 73%, bp 159-161° (0.2 mm), mp 65-67° (lit.²² mp 65-66.5); X = morpholino, 54%, bp 144-150° (0.005 mm), mp 71-73° (lit.²² mp 69.5-70.5°); X = 4-methylpiperazino, 43%, bp 149-152° (0.02 mm), mp 44-48°; picrate (using 1 equiv of picric acid), mp 137.5-138° (MeOH) [Anal. (C₂₀H₂₄N₂O₈)]; X = N(CH₂Ph)₂, 60%, bp 199-203° (0.05 mm) (lit.²⁶ bp 191-193° (0.02 mm)).

4-(β-Diethylaminobutyloxy)aniline. 4-Acetamidophenol and Br(CH₂)₂Br (3 equiv) under conditions D₁ gave 4-(β-bromobutyloxy)acetanilide (45%, mp 100-102° from Me₂CO-hexane). Anal. (C₁₂H₁₆BrNO₂) C, H, Br. This product reacted with Et₂NH under the conditions B₂ to give 4-(β-diethylaminobutyloxy)acetanilide (HCl mp 134-136°, EtOH-Et₂O) which was hydrolyzed (6 N HCl, 3-hr boiling) to the required aniline (yield 22% overall): bp 128-130° (0.01 mm). Anal. (C₁₄H₂₄N₂O).

4-(3-Chloropropyl)aniline was obtd by hydrogenation (10% Pd/C, EtOH, 1 atm) of the NO₂ compd⁴ as an oil: bp 127-128° (1 mm), di-HCl mp 218-219° (lit.²⁷ mp 195.5-196.5°).

4-(β-Diethylaminoethylamino)aniline was similarly obtd (Pt, EtOH, 3 atm) as an oil, bp 120-121° (0.05 mm under N₂), which deteriorated in air.

3-Chloro-4-(β-diethylaminoethoxy)aniline. The NO₂ compd²⁸ was reduced with SnCl₂-conc'd HCl (2 hr, 100°), the mixt was heated with 10 N NaOH for 1 hr at 100° to decomp the Sn complex, and the aniline was isolated by Et₂O extn and dist (75%): bp 151-152° (1 mm), mp 41-42°. Anal. (C₁₂H₁₆ClN₂O) C, H, N, Cl.

4-(β-Diethylaminoethoxy)-3,5-dimethylaniline. 4-(β-Diethylaminoethoxy)-3,5-dimethylnitrobenzene was obtd by method D (63%): bp 164-165° (1 mm), citrate mp 167-168° (MeOH). Anal. (C₂₀H₂₆N₂O₂). Hydrogenation of the base (10% Pd/C, EtOH, 1 atm) gave the aniline (95%): bp 145-146° (0.8 mm), dioxalate mp 165-166° (MeOH-Et₂O). Anal. (C₁₈H₂₈N₂O₂) H; C: calcd, 51.9; N: calcd, 6.7; found, C, 51.3; N, 7.3.

4-(β-Diethylaminoethoxy)-5-isopropyl-2-methylaniline. 4-Acetamidomethyl was alkylated by method D to give 4-(β-diethylaminoethoxy)-5-isopropyl-2-methylacetanilide (27%): mp 86-87° [petr

(60–80°). *Anal.* (C₁₈H₃₀N₂O₂) C, H; 40% of the starting material was recovered. The basic ether was boiled for 1 hr with 6 N HCl to give the aniline as an oil (yield 95%) suitable for the next stage. Distn under N₂ gave a colorless oil: bp 127–128° (0.8 mm). *Anal.* (C₁₆H₂₈N₂O).

ω-Chloroalkoxy (or ω-Chloroalkyl)anilinobenzoxazoles for Methods B–B₄. A 2-chlorobenzoxazole (0.02 mole), a 4-(ω-chloroalkoxy)- or 4-(ω-chloroalkyl)aniline (0.02 mole), and Cl₂CHCHCl₂ (60 ml) were boiled under reflux for 3 hr, cooled, dild with CHCl₃ (30 ml), and washed successively with H₂O, NaHCO₃ soln, and H₂O. During the washing some of the product sepd and was filt'd off. The organic phase was evap'd and more product was obt'd by recrystn of the residue. Thus were obt'd: 2-[4-(β-chloroethoxy)anilino]benzothiazole (85%), mp 173–174° [PhH–petr (60–80°)] [*Anal.* (C₁₅H₁₃ClN₂OS)]; 2-[4-(β-chloroethoxy)anilino]benzothiazole (80%), mp 165–167° (PhH) [*Anal.* (C₁₅H₁₃ClN₂O₂)]; 2-[4-(3-chloropropyl)anilino]benzothiazole (55%), mp 121–123° [PhH–petr (60–80°)] [*Anal.* (C₁₆H₁₅ClN₂S) C, H, N, Cl]; 2-[4-(β-chloroethoxy)anilino]-6-methoxybenzothiazole (53%), mp 146–147° [PhH–petr (60–80°) and EtOH–H₂O] [*Anal.* (C₁₆H₁₅ClN₂O₂S) C, H, N, Cl]; 6-chloro-2-[4-(β-chloroethoxy)anilino]-5-methoxybenzothiazole (30%), mp 177–178° [PhH–petr (60–80°)] [*Anal.* (C₁₆H₁₄Cl₂N₂O₂S) H, N; C: calcd, 52.05; found 52.5].

2-[4-(β-Chloroethoxy)anilino]-5-methoxybenzothiazole. 5-Methoxy-2-methylsulfonylbenzothiazole²⁹ (1105 g), 4-(β-chloroethoxy)aniline (780 g), and PhMe (5 l) were boiled under reflux using a water trap. After 2 hr a further 156 g of the aniline was added and boiling was continued for 4 hr. The product was filt'd off when cool and was washed with EtOH (3 l) to give 1290 g (85%), mp 176–178° which was used for the next stage. Recrystn from CHCl₃ gave mp 183–184°. *Anal.* (C₁₆H₁₅ClN₂O₂S).

2-Mercaptobenzoxazoles were prep'd from 2-aminophenols by a reported method³⁰ to give: 2-mercapto-6-methylbenzoxazole (75%), mp 211–212° (EtOH–H₂O) [*Anal.* (C₈H₉NOS)]; 2-mercapto-5-methylbenzoxazole (73%), mp 221–222° (lit.³¹ mp 216–217°); 5,6-dimethyl-2-mercaptobenzoxazole (65%), mp 219–220° (EtOH) [*Anal.* (C₉H₉NOS)].

2-Mercapto-5-trifluoromethylbenzothiazole. Bis(2-nitro-4-trifluoromethylphenyl)disulfide³² (72 g), H₂O (2 l), conc'd HCl (45 ml), and reduced Fe powder (100 g) were stirred at 80° for 2 hr, allowed to stand overnight, made basic with NaOH soln, washed with Et₂O, and filt'd. The filtrate was acidified with HOAc and the product was isolated by Et₂O extn and dist'd to give 2-amino-4-trifluoromethylbenzenethiol (40%): bp 76–78° (2 mm) [lit.³³ bp 76–78° (2 mm)]. The aminothioli and CS₂ under the usual conditions³⁴ gave 2-mercapto-5-trifluoromethylbenzothiazole (78%): mp 222–224° (EtOH–H₂O and HOAc). *Anal.* (C₈H₆F₃NS₂).

2-Chlorobenzothiazoles and benzoxazoles. 2-Aminobenzothiazoles were treated with HNO₂ and Cu under described condns³⁵ to yield: 2-chloro-4-methylbenzothiazole (45%), mp 40–43° (lit.³⁶ mp 42–43°) and 2-chloro-4-methoxybenzothiazole (40%), mp 67–69° [petr (60–80°)]. *Anal.* (C₈H₆ClNOS) C, H, N, Cl.

5-Acetamido-2-chlorobenzothiazole. 2-Chloro-5-nitrobenzothiazole¹⁰ (6.5 g) was added portionwise during 40 min to a stirred, boiling mixt of EtOH (45 ml), HOAc (3 ml), and Fe powder (15 g). After a further 1 hr, EtOH (60 ml) and charcoal were added, the mixt was boiled for 15 min and filt'd and the residue was ext'd with hot EtOH. The combined liquors were dild with 500 ml of H₂O and after 2 days at 5° the 5-amino-2-chlorobenzothiazole was collected and recryst'd from PhH (2.1 g): mp 145–150°. The amine was acetylated (AcCl, pyridine) to give the title comp'd (2.0 g): mp 169–170° (PhH). *Anal.* (C₉H₇ClN₂OS) C, H, N, Cl.

2,6-Dichloro-5-methoxybenzothiazole. 2-Mercapto-5-methoxybenzothiazole with SO₂Cl₂ under condns reported to give the 2-chloro analog,⁹ gave only a dichloro deriv: mp 128–129° [petr (60–80°)]. *Anal.* (C₈H₆Cl₂NOS).

2-Chloro-5-trifluoromethylbenzothiazole was prep'd from the 2-mercapto comp'd in the usual way⁹ and purified by recrystn (MeOH) and sublimation at 60° (0.1 mm): yield 71%, mp 60–61°. *Anal.* (C₈H₃ClF₃NS) C, H, N, Cl.

2-Chloro-5,6-dimethylbenzoxazole. 5,6-Dimethyl-2-mercaptobenzoxazole (6 g) was added portionwise to a stirred soln of COCl₂ (4 g) in CHCl₃ (14 ml) with DMF (2 drops) at 0°, stirred for 1 hr then set aside overnight. The soln was boiled under reflux with slow passage of COCl₂ for 7 hr and evap'd and the oil ext'd with petr 40–60°. The yellow product [4 g, mp 76–77° from hexane; *anal.* (C₉H₈ClNO) Calcd: C, 59.5, H, 4.4; found, C, 59.15, H, 5.3] was sensitive to atm moisture, giving 5,6-dimethylbenzoxazolone:³⁷ mp 177°

Phenols Used in Method D. 2-(p-Hydroxyphenylalkyl)benzo-

thiazoles and benzoxazoles were obt'd by a described procedure³⁸ from p-methoxyphenylalkanoic acid chlorides and o-aminothiophenol or o-aminophenol, respectively, and demethylation of the intermediate MeO comp'ds with pyridine·HCl,¹⁹ giving the following comp'ds: 2-(p-hydroxyphenethyl)benzoxazole (48%), mp 110–111° (EtOH); 2-(p-hydroxybenzyl)benzothiazole (54% overall), mp 168° (EtOH–H₂O); 2-[3-(p-methoxyphenyl)propyl]benzothiazole (80%), mp 74.5–75.5° (hexane) [*Anal.* (C₁₇H₁₇NOS)]; 2-[3-(p-hydroxyphenyl)propyl]benzothiazole (58%), mp 130° (PhH) [*Anal.* (C₁₆H₁₅NOS)].

2-(p-Hydroxyanilino)benzothiazoles were obt'd by using a p-aminophenol in method A above and neutralizing the HCl soln with NaHCO₃. In this way 2-(p-hydroxyanilino)benzothiazole was ppt'd (85%): mp 205–206° (lit.¹⁹ mp 203–204°) and 2-(4-hydroxy-2-methylanilino)benzothiazole was isolated by EtOAc extn (45%): mp 207–208° (MeOH–H₂O). *Anal.* (C₁₄H₁₂N₂OS).

2-[4-(β-Azidoethoxy)anilino]benzothiazole. A soln of 2-[4-(β-chloroethoxy)anilino]benzothiazole (6.4 g) in DMF (35 ml) was added during 1 hr to a stirred suspension of NaN₃ (5.5 g) in DMF (50 ml) at 95°. After a further 21 hr the soln was conc'd to half vol and dild with H₂O (150 ml), and the ppt was recryst'd from PhH to give 5.45 g (85%): mp 147–148.5°. *Anal.* (C₁₅H₁₃N₃OS).

Acknowledgments. We wish to thank Mrs. Jenifer A. Rees and Mr. R. J. King for technical assistance in pharmacology and chemistry, respectively. We thank Mr. G. Penn of Twyford Pharmaceutical Services Ltd., Basingstoke, England, for the teratology results.

References

- H. D. Cossey, R. N. Gartside, and F. F. Stephens, *Arzneim. Forsch.*, **16**, 33 (1966).
- American Cyanamide Co., British Patent 1,034,538 (1966); *Chem. Abstr.*, **65**, 15,397a (1966).
- C. J. Sharpe, R. S. Shadbolt, A. Ashford, and J. W. Ross, *J. Med. Chem.*, **14**, 977 (1971).
- R. S. Shadbolt, C. J. Sharpe, G. R. Brown, A. Ashford, and J. W. Ross, *ibid.*, **14**, 836 (1971).
- J. D'Amico, C. C. Tung, and L. A. Walker, *J. Amer. Chem. Soc.*, **81**, 5957 (1959).
- E. J. Cragoe, Jr., and C. L. Hamilton, *ibid.*, **67**, 536 (1945).
- C. K. Banks, *ibid.*, **66**, 1127 (1944).
- L. Katz and M. S. Cohen, *J. Org. Chem.*, **19**, 767 (1954).
- N. S. Moon, U. S. Patent 2,469,697 (1949); *Chem. Abstr.*, **43**, 6670c (1949).
- P. E. Todesco and P. Vivarelli, *Gazz. Chim. Ital.*, **92**, 1221 (1962); *Chem. Abstr.*, **59**, 396f (1963).
- F. Sulser and F. Soroko, *Psychopharmacologia*, **8**, 191 (1965).
- R. C. Ursillo and J. Jacobson, *J. Pharmacol. Exp. Ther.*, **148**, 247 (1965).
- D. H. Tedeschi, R. E. Tedeschi, and E. J. Fellows, *ibid.*, **126**, 223 (1959).
- G. M. Everett, *Proc. Symp. Antidepressant Drugs, Ist*, 1966, 164 (1967).
- P. S. J. Spencer, *ibid.*, 1966, 194 (1967).
- J. W. Bastian, W. E. Krause, S. A. Ridlon, and N. Ercoli, *J. Pharmacol. Exp. Ther.*, **127**, 75 (1959).
- C. H. Cashin and H. Jackson, *J. Pharm. Pharmacol.*, **14**, 44T (1962).
- R. C. Elderfield and F. W. Short, *J. Org. Chem.*, **18**, 1093 (1953).
- H. D. Cossey, C. J. Sharpe, and F. F. Stephens, *J. Chem. Soc.*, 4322 (1963).
- W. G. Christiansen and S. E. Harris, U. S. Patent 2,404,691 (1946); *Chem. Abstr.*, **41**, 155d (1947).
- K. Zahn, *Chem. Ber.*, **56**, 578 (1923).
- R. M. Herbst and J. V. Simonian, *J. Org. Chem.*, **17**, 595 (1952).
- P. M. Bugai, *Tr. Kharkov Politekh. Inst.*, **4**, 99 (1954); *Chem. Abstr.*, **52**, 7183i (1958).
- M. Brochmühl, W. Persch, and E. Bartolomaus, U. S. Patent 2,050,557 (1936); *Chem. Abstr.*, **30**, 6893 (1936).
- F. C. Whitmore, H. S. Mosher, R. R. Adams, R. B. Taylor, E. C. Chapin, C. Weisel, and W. Yanko, *J. Amer. Chem. Soc.*, **66**, 725 (1944).
- I. A. Kaye, W. J. Burlant, and L. Price, *J. Org. Chem.*, **16**, 1421 (1951).
- J. Büchi, J. Enézián, G. Valette, and C. Pattani, *Helv. Chim.*

- Acta*, 43, 1971 (1960).
 (28) H. Najer and P. Mabile, *Bull. Soc. Chim. Fr.*, 645 (1958).
 (29) E. Hoggarth, *J. Chem. Soc.*, 3311 (1949).
 (30) J. A. Van Allen and B. D. Deacon, "Organic Synthesis," Collect. Vol. IV, Wiley, New York, N. Y., 1963, p 569.
 (31) P. Jacobson and V. Schenke, *Chem. Ber.*, 22, 3232 (1889).
 (32) Bristol-Myers Co., British Patent 899,584 (1962); *Chem. Abstr.*, 58, 1406b (1963).
 (33) P. J. Palmer, R. B. Trigg, and J. V. Warrington, *J. Med. Chem.*, 14, 248 (1971).
 (34) R. F. Hunter, *J. Chem. Soc.*, 137 (1930).
 (35) V. G. Samolovova, V. G. Ermolaeva, T. V. Gortinskaya, V. G. Yashunskii, and M. N. Shchukina, *Med. Prom. SSSR.*, 13, 23 (1959); *Chem. Abstr.*, 54, 21049i (1960).
 (36) R. P. Vel'tman, *Ukr. Khim. Zh.*, 24, 351 (1958); *Chem. Abstr.*, 52, 20673a (1958).
 (37) W. J. Close, B. D. Tiffany, and M. A. Spielman, *J. Amer. Chem. Soc.*, 71, 1265 (1949).
 (38) H. D. Cossey, J. Judd, and F. F. Stephens, *J. Chem. Soc.*, 954 (1965).

Diuretics. 1. 1-Imidoyl-2-(2- and 3-indolyl)indolines

Yao-Hua Wu,* Walter G. Lobeck, Jr., Richard P. Ryan,

Department of Chemical Research

and Allen W. Gomoll

Department of Pharmacology, Mead Johnson Research Center, Evansville, Indiana 47721.

Received November 18, 1971


A series of 1-imidoyl-2-(2- and 3-indolyl)indolines was synthesized and evaluated for diuretic activity. The compounds were generally prepared by treating various dimers of indoles with carboxamide- POCl_3 adducts. Several 2,3,5,6-tetrahydro-5-(3-indolyl)-1*H*-pyrrolo[2,1-*b*][1,3]benzodiazepines were obtained by a rearrangement reaction. A discussion of structure-activity relationships is presented.

Intensive synthetic work on oral diuretics in the past 2 decades has resulted in several efficient agents exemplified by chlorothiazide,¹ ethacrynic acid,² furosemide,³ spironolactone,⁴ and triamterene.⁵ In spite of the apparent commercial success of these agents, a totally satisfactory diuretic agent has not been attained. In his address for the Third Award in Medicinal Chemistry, Sprague⁶ clearly indicated the necessity for continuous effort of medicinal chemists in this field.




We wish to report a new chemical class of oral diuretics represented by structures I-V.[†] Preliminary pharmacological evaluation has been encouraging in view of selective saluretic, K^+ sparing responses elicited by these compounds. This paper deals with chemical syntheses, biological screening results, and structure-activity relationships of the series.

Chemistry. Compounds I-IV were prepared by treating various dimers of indoles with appropriate carboxamide- POCl_3 adducts.⁷

Indole dimer



Skatole dimer



36, R, R' = H
 37, R = H; R' = CH₃
 38, R, R' = CH₃

Dimerization of Indoles. Indoles are known to dimerize and trimerize in the presence of a protonic acid. The chemistry of this polymerization has been reviewed.⁸

By choosing an appropriate solvent as the reaction medium, we were able to dimerize several indoles with minimal concurrent trimerization. An ideal solvent would dissolve the particular indole to be dimerized, but immediately precipitate the dimer hydrochloride when the solution is treated with gaseous HCl. Purification of an indole dimer hydrochloride by a recrystallization method is not feasible, because in solution the dimer hydrochloride equilibrates with its monomer and trimer, resulting in the formation of a mixture (indole monomer \rightleftharpoons indole dimer \rightleftharpoons indole trimer).

[†]Roman numerals refer to classes of compounds mentioned only in the text. Arabic numerals refer to individual compounds and compounds in the tables.